Opaleye Management Inc. has increased its stake in Grace Therapeutics, Inc. through a series of stock purchases, as reported in a recent SEC filing. This move is significant as it reflects Opaleye's confidence in the growth potential of the pharmaceutical sector, particularly in the context of ongoing developments within Grace Therapeutics.
According to the filing dated October 5, 2026, Opaleye Management acquired a total of 38,796 shares on October 1, 20,000 shares on October 2, and an additional 1,694 shares on October 5. Following these transactions, Opaleye now holds 2,858,657 shares in Grace Therapeutics, representing a substantial ownership stake.
Background
Opaleye Management Inc. is a Boston-based investment firm that primarily focuses on managing investments in various sectors, including pharmaceuticals. The company is registered in Massachusetts and operates under the Central Index Key (CIK) number 0001595855. Grace Therapeutics, Inc., the company in which Opaleye has increased its stake, is classified under the SIC code for Pharmaceutical Preparations [2834]. This classification indicates that Grace is involved in the development and production of pharmaceutical products.
What the Filing Says
The SEC filing reveals that Opaleye Management made these acquisitions at varying prices, with the October 1 shares purchased at an average price of $2.0353, the October 2 shares at $2.0684, and the October 5 shares at $2.06. The filing states, "Represents securities owned directly by Opaleye, L.P. (the 'Fund'). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund." This underscores Opaleye's role as a significant investor in Grace Therapeutics.
Impact
The increased ownership stake by Opaleye Management could have various implications for both the company and the broader pharmaceutical industry. For Grace Therapeutics, this investment signals a vote of confidence from a notable investment firm, which may enhance its reputation and market position. Additionally, Opaleye's actions may influence other investors and stakeholders within the pharmaceutical sector, potentially leading to increased interest in Grace and similar companies.
What's Next
The filing does not say what happens next. However, with Opaleye's recent activity, it is likely that further developments may occur as the company continues to monitor its investments in Grace Therapeutics and the pharmaceutical landscape.